Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03595813 | Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy(IMMUNO-SUP) | completed | N/A | 135 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03623373 | Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | completed | Phase 2 | 13 | Washington University School of MedicineOTHER | 1 | Apr 21, 2026 |
| clinicaltrials |
| NCT03777306 | The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma | completed | N/A | 85 | University of Alabama at BirminghamOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05189093 | Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma | completed | Phase 1 / Phase 2 | 48 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03341520 | Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma(GAZAI) | completed | Phase 2 | 89 | Heidelberg UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04392960 | Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis | completed | N/A | 30 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06418750 | Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study(DELICATESSE) | completed | N/A | 20 | Nantes University HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02719613 | Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | completed | Phase 2 | 67 | Bristol-Myers SquibbINDUSTRY | 13 | Apr 15, 2026 | clinicaltrials |
| NCT03935282 | Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors(AH-HA) | completed | N/A | 645 | Wake Forest University Health SciencesOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT04557150 | A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) | completed | Phase 1 | 225 | Hoffmann-La RocheINDUSTRY | 9 | Apr 13, 2026 | clinicaltrials |
| NCT03236935 | Phase Ib of L-NMMA and Pembrolizumab | completed | Phase 1 | 12 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03984097 | A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) | completed | Phase 1 | 50 | TakedaINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04433156 | VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma | completed | Phase 2 | 26 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT01241734 | Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL(RICER) | completed | Phase 1 / Phase 2 | 18 | Hackensack Meridian HealthOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT01453101 | Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma(Flu-Mel-Vel) | completed | Phase 2 | 54 | Hackensack Meridian HealthOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02405364 | Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction(IFM-CRd) | completed | Phase 2 | 46 | University Hospital, ToulouseOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04081779 | Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study | completed | N/A | 261 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04231448 | Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL(DEB) | completed | Phase 3 | 423 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04488354 | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T | completed | Phase 1 | 16 | Calibr, a division of Scripps ResearchOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT01679119 | Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy(INCA) | completed | Phase 2 | 129 | University College, LondonOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02302495 | Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma(IFM2012-03) | completed | Phase 2 | 32 | University Hospital, LilleOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02626481 | Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma(IFM2014-04) | completed | Phase 2 | 64 | University Hospital, LilleOTHER | 2 | Apr 7, 2026 | clinicaltrials |
| NCT00430365 | Maintenance Therapy Using Lenalidomide in Myeloma(IFM2005-02) | completed | Phase 3 | 614 | University Hospital, ToulouseOTHER | 3 | Apr 6, 2026 | clinicaltrials |
| NCT01067287 | Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation | completed | Phase 2 | 35 | Beth Israel Deaconess Medical CenterOTHER | 2 | Apr 6, 2026 | clinicaltrials |
| NCT01191060 | Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years(IFM/DFCI2009) | completed | Phase 3 | 700 | University Hospital, ToulouseOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02518555 | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 42 | Jennifer WoyachOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05972577 | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | completed | N/A | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT01502085 | Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens(RZD) | completed | Phase 1 / Phase 2 | 25 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT01813227 | A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 | completed | Phase 2 | 7 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT04673617 | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 45 | Artiva Biotherapeutics, Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 / Phase 2 | 12 | CRISPR TherapeuticsINDUSTRY | 2 | Apr 3, 2026 | clinicaltrials |
| NCT01242267 | Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT(Thal/Mel/Vel) | completed | Phase 1 / Phase 2 | 29 | Hackensack Meridian HealthOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02684708 | Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents | completed | Phase 3 | 2,921 | University of GiessenOTHER | 19 | Mar 31, 2026 | clinicaltrials |
| NCT05763563 | Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy | completed | N/A | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04088890 | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | completed | Phase 1 | 52 | Matthew FrankOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT00428142 | Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 95 | NCIC Clinical Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT01846390 | Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma | completed | Phase 1 | 21 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05068440 | Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib | completed | Phase 2 | 65 | BeiGeneINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07493486 | IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study | completed | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04661943 | Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma | completed | Phase 2 | 30 | Ou Bai, MD/PHDOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06391814 | Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01) | completed | N/A | 1 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT01011920 | Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | completed | Phase 2 | 227 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 5 | Mar 19, 2026 | clinicaltrials |
| NCT01315132 | A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies | completed | Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02601313 | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)(ZUMA-2) | completed | Phase 2 | 105 | Kite, A Gilead CompanyINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT03441958 | ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma | completed | Phase 1 / Phase 2 | 19 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02135133 | A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 21, 2026source: clinicaltrials